RA Capital

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases using its proprietary CellSeeker tLNP platform. Its technology deploys targeted lipid nanoparticles conjugated with protein binders—such as antibodies—to reprogram specific cell types within the body, including CAR-T cells, without ex vivo manipulation. The lead candidate, CPTX2309, delivers an anti-CD19 CAR payload to CD8⁺ T cells and aims to reset B cell–driven autoimmune disease, currently in Phase 1 trials.